Stampacchia Otello purchased $29.8M of WWB (indirect holdings)

Stampacchia Otello purchased 1,750,000 indirectly-held shares of WINDWARD BIO GROUP AG (WWB) at $17.00 ($29.75M total) across 2 trades on 2026-11-16.

Original reporting
SEC EDGAR · Stampacchia Otello
Published Nov 18, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$WWB
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The article provides transaction size, price, and post-transaction holdings, but it does not include any new company-specific operational, financial, regulatory, or strategic development.

02

Market read

A director purchase may be mildly supportive sentiment, but without additional fundamental information, it is unlikely to drive a tradable repricing by itself.

03

What to watch

The transaction is described as indirect and under a director role, with no 10b5-1 plan, but the article does not provide context on total holdings, prior trading cadence, or any concurrent company news.

Relevance 8/10Novelty 2/10Timing: filing posted on SEC EDGAR on 2026-11-18, covering trades dated 2026-11-16

Background

This is an SEC Form 4 insider transaction disclosure. Reporter Stampacchia Otello (Director) reports an open-market purchase of WWB shares on 2026-11-16, filed 2026-11-18.

Market effects

None. The filing is a director open-market purchase with no disclosed company-level event.

None.

None.

Counterpoint

Insider purchases can be routine or driven by personal liquidity planning, and this filing provides no new fundamental catalyst.

Key entities

  • Windward Bio Group AG

    Subject of the Form 4 insider transaction disclosure (WWB).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WWBMedAI 8/10

Windward Bio closes $251.2m Nasdaq IPO with Sanofi backing

Windward Bio Group AG (Nasdaq: WWB) closed its IPO, raising $251.2m by selling 11.8m shares at $17 each, including an underwriter option. Sanofi invested $50m in a concurrent private placement. Proceeds will fund trials for lead candidates WIN378 and WIN027. The IPO priced at the midpoint of its $16-$18 range, with net proceeds estimated at $203.8m-$228.0m. Jefferies, TD Cowen, Piper Sandler, and UBS managed the offering. Short interest and insider filings show no red flags.

$WWBHighAI 9/10

Windward Bio raises $251.2M in IPO on Nasdaq

Windward Bio Group AG (WWB) raised $251.2M in its IPO on Nasdaq, selling 11.8M shares at $17 each, including underwriters' over-allotment. Sanofi invested $50M in a private placement. WWB develops antibody treatments for respiratory and skin conditions, with two candidates in clinical trials.

$WWBHighAI 9/10

Windward Bio completes $251m IPO on Nasdaq

Windward Bio Group AG (WWB) completed its IPO on Nasdaq, raising $251.2M by selling 11.8M shares at $17 each, including underwriters' options. Concurrently, it raised $50M in a private placement with Sanofi. The biotech company focuses on antibody medicines for respiratory and dermatologic diseases, with lead candidates in clinical trials.